Abstract
Radiopharmaceuticals are used in procedures of nuclear medicine for the diagnosis and treatment of illnesses. Fluorine-18(18F) is a positron emitter produced in cyclotron. It is used to get 18fluorodeoxyglucose (18F-FDG) that is a radiopharmaceutical utilized in the positron emission tomography scan. The aim of this work was to evaluate the in vitro effect of an extract of Ginkgo biloba extract (EGb) on the distribution in blood cells (BC) and plasma (P) compartments and on the binding to the blood constituents of the 18F-FDG using precipitation with trichloroacetic acid (TCA). EGb was not capable to interfere on the distribution of the 18F-FDG on the BC and P compartments. However, this extract was capable of interfering significantly (p<0.05) on the fixation of the 18F-FDG on IF-P (in all the concentrations tested, P<0.05) and IF-BC in 1% TCA concentration from 14.04±1.13 to 10.23±1.92 (40mg/ml, EGb) and to 9.35 ±1.57 (400mg/ml/EGb), in 5% TCA concentration from 14.83±3.78 to 11.15±1.64 (40mg/ml, EGb) and to 10.23±1.6 (400mg/ml, EGb). In conclusion, the analysis of the results indicates that the EGb was not capable to interfere on the distribution of the 18F-FDG on P and BC compartments, however, alter the fixation of the 18FDG on IF-P and IF-BC. Key words: 18Fluorodeoxyglucose, blood compartments, radiopharmaceutical, Ginkgo biloba, medicinal plants.  
Highlights
Radiopharmaceuticals or radiobiocomplexes are employed in nuclear medicine for diagnostic and/or treatment of diseases or to study blood flow, morphology of organs, bioavailability and metabolism of drugs (Saha, 2010)
An important step to understand the mechanism of localization of radiopharmaceuticals in a specific target, as well as they are cleared from blood or eliminated from the body or the rate at which their excretions occur, it is
The secure determination of the binding of radiopharmaceuticals to the plasma (P) and blood cell (BC) constituents can aid to understand the interference of various conditions on the distribution of radiopharmaceuticals in the body (Saha, 2010)
Summary
Radiopharmaceuticals or radiobiocomplexes are employed in nuclear medicine for diagnostic and/or treatment of diseases or to study blood flow, morphology of organs, bioavailability and metabolism of drugs (Saha, 2010). An important step to understand the mechanism of localization of radiopharmaceuticals in a specific target, as well as they are cleared from blood or eliminated from the body or the rate at which their excretions occur, it is. The determination of their binding to the blood proteins. The secure determination of the binding of radiopharmaceuticals to the plasma (P) and blood cell (BC) constituents can aid to understand the interference of various conditions on the distribution of radiopharmaceuticals in the body (Saha, 2010). To investigate the radiobiocomplexes-protein binding, these complexes of protein-bound-radiobiocomplex must be separated from the free radiobiocomplex. This has been accomplished by precipitation of the proteins with precipitating agents, as trichloroacetic acid (TCA) (Freitas et al, 2007) or ethanol (Fernandes et al, 2007)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
